Skip to main content
main-content

Neuer Inhalt Free Registration

Gain full access to the latest clinical content available from Springer Nature

Editors' pick

21-11-2017 | Glioblastoma multiforme | News

Bevacizumab add-on fails to improve glioblastoma OS with lomustine

Adding bevacizumab to lomustine does not prolong overall survival compared with lomustine alone in patients with progressive glioblastoma, but may delay disease progression, show phase III study data.

01-11-2017 | E-Learning | Collection

EGFR inhibitors and cutaneous complications: A practical approach to management

This CME module is intended to help healthcare professionals learn to recognize and manage the most common cutaneous side effects associated with epidermal growth factor receptor therapy.

03-10-2017 | PARP inhibitors | Themed collection | Collection

PARP inhibitors

This Themed Collection highlights the role of poly(ADP-ribose) polymerase (PARP) I in DNA repair, and provides a review of clinical evidence for PARP inhibitors in the treatment of cancer.

Latest from across the site

24-11-2017 | Head and neck cancers | News

Long-term neurocognitive problems a concern for head and neck cancer survivors

Head and neck cancer survivors are at risk for delayed neurocognitive deficits for at least 2 years after radiotherapy or chemotherapy, according to a prospective longitudinal study.

Source:

JAMA Otolaryngol Head Neck Surg 2017; Advance online publication

23-11-2017 | FDA | Drug approval | News

approvalsWatch

FDA announces approvals for sunitinib, obinutuzumab

More details on these decisions are a click away

23-11-2017 | Anal cancer | News

Anal cancer burden high among people with HIV

People with HIV infection are nearly 20 times more like to develop anal cancer than those in the general population, study findings indicate.

Source:

J Clin Oncol 2017; Advance online publication

21-11-2017 | Glioblastoma multiforme | News

Bevacizumab add-on fails to improve glioblastoma OS with lomustine

Adding bevacizumab to lomustine does not prolong overall survival compared with lomustine alone in patients with progressive glioblastoma, but may delay disease progression, show phase III study data.

Source:

N Engl J Med 2017; 377: 1954–1963

20-11-2017 | Non-small cell lung cancer | News

No survival gain with bevacizumab in NSCLC adjuvant treatment

Trial findings indicate that adding bevacizumab to adjuvant chemotherapy does not improve survival for patients with surgically resected early-stage, non-small-cell lung cancer.

Source:

Lancet Oncol 2017; Advance online publication

17-11-2017 | FDA | News

approvalsWatch

Dasatinib receives pediatric CML go-ahead

Read more on this US FDA approval here

Latest from us on Twitter

Updates from oncology organizations

Meet our Advisory Board

image credits